Visualization and a smaller package

Article

The new 23G endoscope proves it's flexibility: A case study

Ocular inflammation is a ubiquitous symptom that could have any number of causes, and improved visualization within the eye is often imperative to correct diagnosis. I was recently referred a patient diagnosed with pseudoexfoliation syndrome and had undergone cataract surgery five years previously. The patient had undergone multiple vitrectomy surgeries for the chronic inflammation, and a wide-angle viewing system and scleral depression at the time of the earlier vitrectomies did not reveal an aetiology. Intraocular lymphoma was suspected and the patient was referred to me to undergo an endoscopic vitrectomy.

This case could be compared to severe endophthalmitis where the anterior segment view is compromised. Without an endoscope the physician would have to remove infected material almost blindly, resulting in the debulking of relatively little of the toxic infectious and/or inflammatory debris. While these are eyes with low visual potential, using the endoscope enables the physician to achieve a far greater removal of the damaging material, and increases the likelihood of saving the eye and preserving at least some vision.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.